CordenPharma Chenôve Receives Successful FDA Inspection
CordenPharma is pleased to announce that their CordenPharma Chenôve (France) manufacturing facility recently completed an FDA Inspection and received a successful response with no 483s reported. The last FDA Inspection took place in 2014. Yves Michon, Managing Director of CordenPharma Chenôve comments, “We are pleased with the outcome of the FDA Inspection in August 2016, as it reflects our willingness to comply with the highest level of cGMP regulatory compliance while continuously improving our standards for our customers and their projects going forward.”
About CordenPharma
CordenPharma International, a pharmaceutical brand of International Chemical Investors Group (ICIG), is a full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. Through a network of fully-inspected cGMP facilities across Europe and the US organized under five technology platforms – Peptides, Lipids & Carbohydrates, Injectables, Highly Potent & Oncology, Small Molecules, Antibiotics – CordenPharma experts translate complex ideas at any stage of development into high-value products.www.cordenpharma.com. Inquiries: www.cordenpharma.com/contact-us/
CordenPharma Chenôve, one of multiple CordenPharma facilities across Europe and the US, is a cGMP manufacturer of APIs and advanced pharmaceutical intermediates, specializing in the design of synthetic routes and development processes for new products, with equipment and chemical technologies particularly suitable for multi-step synthesis from laboratory to commercial scale. www.cordenpharma.com/facilities/chenove/
Media Contact
CordenPharma
Abby Thompson
T +1 (617) 909-5312
abby.thompson@cordenpharma.com
Total Page Views: 981
